Mariana Muñoz-Esquerre

Mariana Muñoz-Esquerre

Auto-generated profile, based on publicly available information

Mariana Muñoz-Esquerre

Respiratory Department, Bellvitge University Hospital - IDIBELL, Barcelona, Spain; University of Barcelona, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 May 2021 in Journal of Asthma
Verified
Journal Article
Closed access
CRCarlos Martinez Rivera
Carlos Martinez Rivera
ACAstrid Crespo-Lessmann
Astrid Crespo-Lessmann
EAEbymar Arismendi
Ebymar Arismendi
MMMariana Muñoz-Esquerre
Mariana Muñoz-Esquerre
XAXavier Aguilar
Xavier Aguilar
XMXavier Muñoz
Xavier Muñoz
To develop a set of recommendations for the management of severe asthma during COVID-19 pandemic. Eleven pneumologists and allergologists who were staff members of officially accredited asthma units in Catalonia (Spain) participated in a cross-section study based on three 2-hour virtual workshops (first: brainstorming, second: identification of impacts and challenges summarized in 10 topics, third: establishment of final recommendations by consensus). Impacts and challenges identified were improvement of referral protocols between different levels of care; assessment of the minimum number of function tests to be performed and promote the performance of spirometry in primary care; implementation of videoconferencing, mobile apps, telephone calls, or integral virtual platforms for the follow-up of patients, and definition of the model of care (face-to-face, telematics, mixed) according to the patient’s individual needs; self-administration of biologics for domiciliary treatment; and empowerment of the role of nursing and hospital pharmacy in particular for follow-up and self-administration of biologics. The main recommendations included coordination between primary care and specialized care consultation, optimization of lung function testing, implementation of telemedicine, and the role of nursing and hospital pharmacy. The specific proposals in response to the effect of COVID-19 pandemic focused on four areas of interest (coordination between primary care and specialized care, optimization of lung function testing, implementation of telemedicine, and empowerment of the role of nursing and hospital pharmacy) may be generalized to other health care settings, and help to introduce new ways of caring asthma patients in the COVID-19 context.

13 February 2025 in Journal of Asthma
Verified
Journal Article
Open access
Eva María Martínez PérezEva María Martínez Pérez
Eva María Martínez Pérez
CPCelia Pinedo-Sierra
Celia Pinedo-Sierra
LMLuis Puente MAestu
Luis Puente MAestu
MMMariana Muñoz-Esquerre
Mariana Muñoz-Esquerre
AFAna Gómez-Bastero Fernández
Ana Gómez-Bastero Fernández
SQSantiago Quirce
Santiago Quirce
Asthma and severe asthma are problems affecting all age groups, but asthma is frequently undiagnosed in the elderly, due to the poor perception of airflow limitation, lack of fitness, and presence of multiple comorbidities.Even so, the proportion of patients with severe asthma aged ≥65 is significant, and data on efficacy of asthma medications in the elderly are sometimes limited. We report here the effectiveness and safety of mepolizumab (an IL-5 inhibitor) in elderly (≥ 65 years) patients. The REDES study was an observational, multicenter study of the effectiveness and safety of mepolizumab 100mg SC every 4 weeks in 318 severe asthma patients in Spain. This post-hoc analysis compares the effectiveness and safety of patients ≥65 years old to patients <65 years after 12 months of mepolizumab treatment. 27% of patients were ≥65 years old, compared with 73% of patients <65 years. Elderly patients showed a trend towards less frequent comorbid nasal polyps (p = 0.06) and a lower proportion of atopic sensitization (as detected by prick test or specific IgE) (p = 0.02). Similar improvements were noted in ACT score (p < 0.0001), comparable exacerbation reductions (p < 0.0001) and lung function parameters (p < 0.04 in elder group and p < 0.0001 in younger elder group), although an apparent greater reduction of OCS daily dose was observed in elder patients (p = 0.0002). No new safety signals were reported in the elderly population. This study further supports mepolizumab as an effective and well tolerated therapy in the difficult to treat population of elderly patients with severe asthma.

4 June 2025 in Multidisciplinary Respiratory Medicine
Verified
Journal Article
Open access
PDF file
HCHéctor Cabrerizo Carreño
Héctor Cabrerizo Carreño
CACristina Bellver Asperilla
Cristina Bellver Asperilla
ARAna Maria Romero-Ortiz
Ana Maria Romero-Ortiz
SSSalud Santos
Salud Santos
SASamantha Aso-González
Samantha Aso-González
MMMariana Muñoz-Esquerre
Mariana Muñoz-Esquerre
Background: Home spirometry using portable devices offers a potential alternative for asthma management by reducing hospital dependence and improving accessibility. This study aimed to assess the feasibility of a home spirometry program with bronchodilator response (BDR) testing performed without direct medical supervision. Methods: A prospective observational study was conducted with 47 asthma patients from a tertiary hospital. Participants received clear instructions and performed forced spirometry with BDR testing at home using a portable device. The primary outcomes included spirometry quality, variability compared to hospital tests, and patient satisfaction. Results: A total of 78% of participants achieved high-quality spirometry (A or B, according to ATS/ERS ­criteria), despite greater variability in forced vital capacity (FVC) and forced expiratory volume in 1 second (FEV1) compared to hospital tests. However, the results remained clinically acceptable. Patients reported high satisfaction with the device, highlighting its ease of use and convenience. Conclusions: Home spirometry with BDR testing is a feasible tool for asthma follow-up, maintaining acceptable quality while reducing hospital-based testing. Although improvements are needed to minimize variability and enhance consistency, this program has the potential to optimize asthma management, increase accessibility, and reduce the burden on healthcare facilities.

24 April 2026 in Respiratory Medicine
Verified
Journal Article
Open access
CBCristina Bellver-Asperilla
Cristina Bellver-Asperilla
AOAna Romero Ortíz
Ana Romero Ortíz
HCHéctor Cabrerizo-Carreño
Héctor Cabrerizo-Carreño
SESandra Orozco Echeverría
Sandra Orozco Echeverría
XGXavier Gonzalez-Compta
Xavier Gonzalez-Compta
MMMariana Muñoz-Esquerre
Mariana Muñoz-Esquerre
Data from real-life settings regarding dupilumab-associated eosinophilia remains limited, particularly concerning potential risk factors for developing hypereosinophilia after treatment initiation. We conducted a prospective observational study including an initial cohort of 36 patients with severe asthma treated with dupilumab and followed for up to two years. Blood eosinophil count (BEC), asthma outcomes, and treatment response - including ACT score, lung function, exacerbations, oral corticosteroid use, and the EXACTO scale as a multidimensional response measure - were assessed at baseline and at weeks 24, 52, and 104. Eosinophilia was categorized as mild (>500 cells/μL), moderate (>1500 cells/μL), or severe (>5000 cells/μL), and hypereosinophilia as moderate-severe eosinophilia. Transient eosinophilia occurred in 47.2% of patients and transient hypereosinophilia in 19.4%, with most cases being asymptomatic. Two patients (5.6%) developed a clinical presentation suggestive of eosinophilic granulomatosis with polyangiitis (EGPA). Hypereosinophilia was more frequent among patients who had switched from prior anti-IL-5/IL-5R therapy. Among the cases that developed hypereosinophilia, 42.9% persisted at the 2-year follow-up, whereas mild eosinophilia persisted in 65% of patients. Nevertheless, dupilumab treatment resulted in significant improvements in asthma control and treatment response outcomes, irrespective of eosinophil levels or prior biologic exposure. Eosinophilia is a common finding in patients receiving dupilumab, generally without significant safety implications. The use of dupilumab is safe and highly effective, even in patients previously treated with anti-IL-5/IL-5R biologics. However, rare cases of severe eosinophilic complications may occur, making long-term systematic monitoring advisable.

6 February 2026 in Revista de Asma
Verified
Journal Article
Closed access
MMMariana Muñoz-Esquerre
Mariana Muñoz-Esquerre
Los avances en nanotecnología impulsan terapias inhaladas para el asma basadas en nanopartículas y fragmentos de anticuerpos, que ofrecen ventajas frente a los anticuerpos convencionales por su menor tamaño, mejor penetración epitelial y producción más eficiente. Al dirigirse directamente al epitelio de la vía aérea, esta estrategia permite una acción localizada, con altas concentraciones pulmonares y exposición sistémica limitada, mejorando potencialmente el índice terapéutico y reduciendo efectos adversos. Sin embargo, el desarrollo de estos fármacos se enfrenta a importantes barreras tecnológicas, fisicoquímicas y biológicas. Una deposición pulmonar eficaz exige un control preciso del tamaño aerodinámico de las partículas, mientras que los procesos de formulación y aerosolización pueden comprometer la estabilidad estructural de las proteínas, favoreciendo la agregación y aumentando el riesgo de inmunogenicidad. A estas limitaciones se suman mecanismos de aclaramiento pulmonar, como el moco y el aclaramiento mucociliar, la actividad proteolítica, la fagocitosis por macrófagos alveolares y la presencia de biofilm bacteriano, que puede reducir la absorción transepitelial y la biodisponibilidad del fármaco, y hacen crítica la optimización del dispositivo y de la formulación. La evidencia clínica es heterogénea, ya que los primeros ensayos con anti-IgE inhalado no demostraron eficacia y plantearon problemas de seguridad, mientras que los fragmentos inhalados dirigidos frente a IL-13 y TSLP han mostrado actividad farmacodinámica local y buena tolerabilidad en fases tempranas. Los biológicos inhalados (BI) son una aproximación prometedora, cuyo éxito dependerá de demostrar un beneficio clínico claro, garantizar una buena adherencia terapéutica y ajustarse a la complejidad del asma en el contexto de la medicina personalizada.

25 August 2026 in Journal of Asthma
Verified
Journal Article
Closed access
MGMiguel Jiménez Gómez
Miguel Jiménez Gómez
CACarlos Almonacid
Carlos Almonacid
MAMARINA BLANCO APARICIO
MARINA BLANCO APARICIO
HIHemily Katerine Izaguirre-Flores
Hemily Katerine Izaguirre-Flores
MMMariana Muñoz-Esquerre
Mariana Muñoz-Esquerre
JSJosé Gregorio Soto-Campos
José Gregorio Soto-Campos
A critical step in the management of uncontrolled severe asthma—estimated to affect 3–4% of asthma patients (1)—is the identification of the inflammatory phenotype. Severe asthma is a heterogeneous...